Figure 6.

CCT196969 and CCT241161 Inhibit Tumors with Acquired Resistance to Dabrafenib plus Trametinib

(A) pERK and pSFK in PDX from patient #13 before and after treatment with dabrafenib plus trametinib. Scale bars, 100 μm.

(B) Sequencing electropherograms confirming BRAF^V600E and NRAS^Q61R mutations in PDX from patient #13.

(C) Growth of PDX from patient #13 in NSG mice treated with dabrafenib plus trametinib (dab + tram), CCT196969, or CCT241161 21 days after tumor implant. ^∗∗∗p ≤ 0.001 (t test, two-tailed).

Bars represent SEM. See also Figure S6.